Regenerative medicines and associated therapies can help mammalian cells to reconstruct: reconstruction of lost limbs, human cells, tissues and tendons, or even undo organ problems. Regenerative medicines have emerged as a promising field of tissue engineering and refers to the practice of providing treatments to repair, regenerate, and replace damaged cells and tissue. The numerous applications include offering therapies for complex diseases such as Alzheimers and spinal injuries or providing cures for chronic ones like cancer and diabetes. The trend of restoring damaged tissues is evident in spray-on skin and lab-grown ears, with the terms tissue engineering and regenerative medicine used interchangeably.
The benefits of regenerative medicines seemingly extend over medical applications to non-therapeutic ones such as biosensors which are employed to detect biological or chemical threat agents, or biomaterial chips that can assess the toxic effects of a medication. One of the main goals of this emerging field is to improve people’s quality of life and restoring them back to a normal functional state.
Researchers world have already been experimenting with stem cells for long. These progenitor cells can develop into several types of tissue, thereby driving the bodies to heal themselves. Some of the early and most promising clinical trials involved treating congestive heart diseases and regrowing muscles in soldiers who were severely wounded in war. Advances in stem cells especially related to pluripotent cells to treat various regenerative disorders focuses on stem cells that can turn into any kind of cell and is a key factor triggering the growth of the regenerative medicines market.
See related Press Release: http://goo.gl/aHFjeB
See related Press Release: http://goo.gl/aHFjeB
Regenerative medicines evolving as a multidisciplinary field of biomaterials incorporates nanotechnology as a potent tool to produce material structures that mimic the biological ones capable of providing very efficient delivery systems. The fabrication of materials, such as nanoparticles and scaffolds used for tissue engineering, and the nanopatterning of surfaces can help get “in vivo” in response to the biological signals mammalian cells receive from the surroundings. The applications of stem cells to harness the power of regenerative medicines for curing diseases such as frontotemporal dementia and amyotrophic lateral sclerosis (ALS) look for collaborative findings to help researchers to discover new approaches. Last month, two collaborative teams within USC Stem Cell bagged an award Audrey E. Streedain Regenerative Medicine Initiative Awards. The magnanimous award which summed up to $140,000 each support faculty members affiliated to USC who is keen on multi-investigator research collaborations with the goal of curing diseases using stem cells as potent tools. The eminent researchers Justin Ichida and Paula Cannon, with Department of Stem Cell Biology and Regenerative Medicine, aim to develop a powerful technique for which can help to rectify a gene mutation responsible for 10 % of all cases of ALS & frontotemporal dementia . According to Cannon “These grants are pretty unique in that they allow the type of high-risk research that isn’t feasible without collaboration,”
Various alliances have cropped up recently this year that hope to the bridge the gap between the academia and industry so that the ongoing R&D activities can translate to effective patient care using regenerative medicine.
The Rare Disease Clinical and Patient Education Roundtable which took place on 27th January in Washington is focused on educating multi-sector stakeholders regarding the growth prospects of regenerative medicine market and large scale applications to cure various rare diseases. The event, first of its kind, is announced by the Alliance for Regenerative Medicine (ARM), an international organization representing the researches on gene therapy, cell therapy and tissue engineering. Such collaborations and joint events will tend to increase in future, as the technology progresses and results of cutting-edge research and clinical trials are made public. No doubt, dominant strategy adopted by companies is approval required to initiate clinical trials, continuation of trials and for the commercialization of these therapies. As per a recent report by Allied Market Research gene therapies are expected to be the fastest emerging technology, growing at a CAGR of 28.6% during 2014-2020 forecast period.
